Jiayu Zou^1,2,3, Yajie Lu³, Jiaqi Li³, Zhaokai Zhou^4,5, Fu Peng³, Pu Qiu^2,*, Hailin Tang⁶, Cheng Peng^1,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071940 - 19 January 2026

Abstract Lung cancer is the most common but fatal malignant tumor worldwide. Patients with lung cancer experienced a relatively low 5-year overall survival rate, and issues such as metastasis and drug resistance remain prominent challenges in its clinical management. Neddylation, a novel type of post-translational modification, was overactivated in lung cancer and was closely associated with its occurrence, development, metastasis, and drug resistance. This review systematically summarizes the biological process of neddylation and deeply explores the latest research progress on how neddylation affects lung cancer cell proliferation, metastasis, and drug resistance mechanisms, with a focus on More >

Ping Wang^1,2,#, Yan-Han Chen^1,2,#, Ze-Tao Zhan^1,2, Jun-Xiang Zeng^1,2, Yu Chen^3,4, Yuan Lin^1,2, Tao Chen^1,5,*, Wei-Jie Zhou^1,2,5,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071902 - 19 January 2026

Abstract Background: Thimerosal is a mercury-containing preservative widely used in vaccines. This study aimed to investigate its potential antitumor effects and mechanisms in solid malignancies, particularly colorectal cancer (CRC) and melanoma. Methods: A combination of in vitro and in vivo approaches was employed. Cell proliferation, apoptosis, migration, and invasion were assessed using Cell Counting Kit-8 (CCK-8), colony formation, ATP viability, Western blotting, flow cytometry, wound-healing and Transwell assays. Subcutaneous, lung metastases, and Azoxymethane/Dextran Sulfate Sodium Salt (AOM/DSS)-induced colitis-associated CRC models were established to examine antitumor efficacy and safety. The functional role of mercury ions was validated using structural… More >

Marta Pawłowska^1,*, Dorian Jarek², Jan Milanowski², Karolina Szewczyk-Golec¹

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071891 - 19 January 2026

Abstract Parasitic infections are increasingly recognized as contributors to cancer development, yet the underlying oncogenic mechanisms remain insufficiently understood. Growing evidence from molecular oncology, immunology, and microbiome research suggests that chronic parasitic infections may drive tumorigenesis through sustained inflammation, deregulated signaling pathways, genomic instability, and the release of parasite-derived exosomes that reshape the tumor microenvironment. These insights underscore the need to integrate parasitology with cancer biology to understand infection-associated malignancies better. The aim of this narrative review is to synthesize current knowledge on how selected parasites contribute to cancer development and to highlight emerging therapeutic and… More > Graphic Abstract

Min Hee Kim¹, Boyoon Huh¹, Joo-Won Park^1,*, Woo-Jae Park^2,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071523 - 19 January 2026

Abstract Breast cancer is one of the most prevalent malignancies among women and comprises a heterogeneous spectrum of molecular subtypes with distinct biological behaviors. Among various regulatory molecules, sphingolipids play pivotal roles in dynamically modulating fundamental cellular processes such as proliferation, apoptosis, and metastasis through metabolic interconversions, including phosphorylation, glycosylation, and the generation of sphingosine-1-phosphate. This review aims to elucidate the mechanisms through which sphingolipid metabolism orchestrates cancer cell fate and drives breast cancer progression. Particular emphasis is placed on the balance between proapoptotic ceramides and pro-survival metabolites, such as sphingosine-1-phosphate, which collectively influence tumor growth More >

Harpreet Kaur^1,*, Dhrubalochan Rana², Sowvik Bag², Paramjeet Singh³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071209 - 19 January 2026

Abstract The prolonged and intricate history of oncological treatments has transitioned significantly since the introduction of chemotherapy. Substantial therapeutic benefits in cancer therapy have been achieved by the integration of conventional treatments with molecular biosciences and omics technologies. Human epidermal growth factor receptor, hormone receptors, and angiogenesis factors are among the established therapies in tumor reduction and managing side effects. Novel targeted therapies like KRAS G12C, Claudin-18 isoform 2 (CLDN18.2), Trophoblast cell-surface antigen 2 (TROP2), and epigenetic regulators emphasize their promise in advancing precision medicine. However, in many cases, the resistance mechanisms associated with these interventions… More > Graphic Abstract

Ruoxue Cai^1,#, Shuyi Hu^2,#, Feiyang Li², Huanhuan Sha^3,*, Guoren Zhou^2,*, Ying Fang³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070893 - 19 January 2026

Abstract Objective: To determine whether immunotherapy can bring new hope for patients with limited-stage small-cell lung cancer (LS-SCLC). We conducted this retrospective study to evaluate whether immunotherapy can achieve better efficacy in LS-SCLC patients. Methods: We evaluated 122 LS-SCLC patients who received concurrent chemoradiotherapy (CCRT) or sequential chemoradiotherapy (SCRT) (Group A) and immunotherapy combined with CCRT/SCRT followed by immunotherapy (Group B), to assess the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Factors affecting prognosis were also explored using Cox analysis. The prognosis of patients with type 2 diabetes and patients with… More >

Shail Rakesh Modi, Terrick Andey^*, George Acquaah-Mensah^*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070793 - 19 January 2026

Abstract Objectives: The current treatment options and therapeutic targets for triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer (BrCA), are limited. This study aimed to identify novel biomarkers and transcriptional regulatory networks (TRN) inherent in TNBC samples. Methods: We analyzed pan-cancer BrCA datasets from The Cancer Genome Atlas (TCGA) to compare triple-positive breast cancer (TPBC) with TNBC. TRN algorithms and virtual inference of protein-enriched regulon (VIPER) were used to identify master regulators and their target genes. Utilizing TNBC cells (MDA-MB-231 and MDA-MB-468), we validated the relationship of nuclear factor erythroid 2-like 3 (NFE2L3) and… More > Graphic Abstract

Mariana Francisco¹, Fernando Mendes^1,2,3,4,5,*, Diana Martins^1,2,3,4, Joana Liberal^1,2

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070276 - 19 January 2026

Abstract Objectives: Colorectal cancer (CRC) is a major global health burden, and Urolithin A (Uro-A) has emerged as a promising anticancer agent. This systematic review aims to synthesize current in vitro evidence on the anticancer effects of Uro-A in CRC, highlighting effective concentration ranges, exposure times, relevant outcomes, and underlying molecular mechanisms. Methods: Following PRISMA 2020 guidelines, a systematic search was conducted in PubMed, Scopus, and Web of Science using the following strategy: (colorectal cancer) AND (urolithin a) OR (3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one). Eligibility criteria were defined by the PICO framework: (P) in vitro CRC cell models; (I) Uro-A alone or… More > Graphic Abstract

Katerina Ondraskova^1,2, Matous Cwik³, Ondrej Horky⁴, Jitka Berkovcova⁴, Jitka Holcakova¹, Martin Bartosik¹, Tomas Kazda⁵, Klara Mrazova^1,6, Michal Uher⁷, Igor Kiss³, Roman Hrstka^1,3,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070116 - 19 January 2026

Abstract Objectives: Cancer treatment relies heavily on accurate diagnosis and effective monitoring of the disease. These processes often involve invasive procedures, such as colonoscopy, to detect malignant tissues, followed by molecular analyses to determine relevant biomarkers. This study aimed to evaluate the clinical performance of droplet digital PCR (ddPCR) for detecting Kirsten Rat Sarcoma Viral Proto-Oncogene (KRAS), Neuroblastoma RAS Viral Oncogene Homolog (NRAS), and B-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in circulating tumor DNA (ctDNA) from colorectal cancer patients using liquid biopsy. Methods: ctDNA was isolated from colorectal cancer (CRC) patients (n = 110) and analyzed for KRAS, BRAF,… More >

Marco Siringo^1,2,#,*, Michela De Meo^1,#, Alain Jonathan Gelibter³, Chiara Nicolazzo^4,5,§, Paola Gazzaniga^5,§

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.069832 - 19 January 2026

Abstract Objectives: Although immune checkpoint inhibitors (ICIs) and targeted therapies have reshaped treatment non-small cell lung cancer (NSCLC) paradigms, prognosis remains poor for many patients due to delayed diagnosis and resistance mechanisms. Liquid biopsy offers a minimally invasive approach to monitoring tumor evolution. Among circulating biomarkers, circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAM-Ls) may provide complementary prognostic insights. The study aimed to evaluate the prognostic role of CTC and CAM-Ls dynamic in metastatic NSCLC patients. Methods: We retrospectively analyzed 77 patients with metastatic NSCLC who underwent CTC and CAM-L evaluation via the CellSearch® system… More >